
## Dongjoon Ko

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10022841/publications.pdf Version: 2024-02-01



#	Article	IF	Citations
1	Therapeutic effects of TM4SF5-targeting chimeric and humanized monoclonal antibodies in hepatocellular and colon cancer models. Molecular Therapy - Oncolytics, 2022, 24, 452-466.	4.4	3
2	TMEM52B suppression promotes cancer cell survival and invasion through modulating E-cadherin stability and EGFR activity. Journal of Experimental and Clinical Cancer Research, 2021, 40, 58.	8.6	8
3	Bovine Serum Albumin-Immobilized Black Phosphorus-Based γ-Fe2O3 Nanocomposites: A Promising Biocompatible Nanoplatform. Biomedicines, 2021, 9, 858.	3.2	6
4	TMPRSS4 promotes cancer stem–like properties in prostate cancer cells through upregulation of SOX2 by SLUG and TWIST1. Journal of Experimental and Clinical Cancer Research, 2021, 40, 372.	8.6	31
5	Anti-cancer activity of the novel 2-hydroxydiarylamide derivatives IMD-0354 and KRT1853 through suppression of cancer cell invasion, proliferation, and survival mediated by TMPRSS4. Scientific Reports, 2019, 9, 10003.	3.3	22
6	Cooperation between ZEB2 and Sp1 promotes cancer cell survival and angiogenesis during metastasis through induction of survivin and VEGF. Oncotarget, 2018, 9, 726-742.	1.8	16
7	Anti-cancer Activity of Novel TM4SF5-Targeting Antibodies through TM4SF5 Neutralization and Immune Cell-Mediated Cytotoxicity. Theranostics, 2017, 7, 594-613.	10.0	19
8	TMPRSS4 induces invasion and proliferation of prostate cancer cells through induction of Slug and cyclin D1. Oncotarget, 2016, 7, 50315-50332.	1.8	31